Tc-99m-tetrofosmin scintigraphy: An alternative scintigraphic method for following up differentiated thyroid carcinoma - Preliminary results

NuklearMedizin

Volumn 35, Issue 6, 1996, Pages 230-235

  Gallowitsch, H J ^a,b   Kresnik, E ^a   Mikosch, P ^a   Pipam, W ^a   Gomez, Iris ^a   Lind, P ^a  

^a LKH Klagenfurt ^*  (Austria)

^b GENERAL HOSPITAL KLAGENFURT   (Austria)

Author keywords

differentiated thyroid carcinoma; Tc 99m sestamibi; Tc 99m tetrofosmin; Tl 201

Indexed keywords

IODINE 131; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; TETROFOSMIN TC 99M; THYROGLOBULIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; THYROID CARCINOMA; THYROID SCINTISCANNING;

EID: 0030456787     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1629781     Document Type: Article

References (24)

1. Balachandran S, Sayle BA. Value of thyroid carcinoma imaging after therapeutic doses of radioiodine. Clin Nucl Med 1981; 6: 162-7.
2. Biedermann M, Bares R, Grün B, et al. Follow-up of thyroid cancer by MRI and Tc-99m-MIBI oncoscintigraphy. Nuklearmedizin 1995; 34: 87-91.
3. Brendel AJ, Guyot M, Jeandot R, et al. Thallium-201 imaging in the follow-up of differentiated thyroid carcinoma. J Nucl Med 1988; 29: 1515-20.
4. Brendel AJ, Guyot M, Jeandot R, et al. Tc-99m MIBI imaging in the follow-up of differentiated thyroid carcinoma. 36th Annual Meeting. J Nucl Med 1989; 30: 904-5.
5. Briele B, Hotze A, Kropp J, et al. Comparison of Tl-201 and Tc-99m MIBI in the follow-up of differentiated thyroid carcinomas. Nuklearmedizin 1991; 30: 115-24.
6. Burman KD, Anderson JH, Wartofsky L, et al. Management of patients with thyroid carcinoma: Application of Thallium-201 scintigraphy and magnetic resonance imaging. J Nucl Med 1990; 31: 1958-64.
7. Charkes ND, Vitti RA, Brooks K. Thallium-201 SPECT increases detectabitlity of thyroid cancer metastases. J Nucl Med 1990; 31: 147-53.
8. Chiu MI, Kronauge JF, Piwinca-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutyl isonitrile) technetium in cultured mouse fibroblasts. J Nucl Med 1990; 31: 1646-53.
9. Civelek AC, Durski K, Shafique I, et al. Failure of perchlorate to inhibit Tc-99m isonitrile binding by the thyroid during myocardial perfusion studies. Clin Nucl Med 1991; 16: 358-61.
10. Highley B, Smith FW, Smith T, et al. Technetium-99m-1,2-bis[bis(2-Ethoxy-ethyl)Phosphino]Ethane: Human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J Nucl Med 1993; 34: 30-8.
11. Hoefnagel BA, Delprat CC, Marcuse HR, de Vijlder JJM. Role of Thallium-201 total-body scintigraphy in follow-up of thyroid carcinoma. J Nucl Med 1986; 27: 1854-7.
12. Kelly D, Forster A, Highley B, et al. Technetium-99m-Tc-99m-tetrofosmin as a new radiopharmaceutical for myocardial perfusion imaging. J Nucl Med 1993; 34: 222-7.
13. Lebouthillier G, Morais J, Picard M. et al. Tc-99m-sestamibi and other agents in the detection of metastatic medullary carcinoma of the thyroid Clin Nucl Med 1993; 18; 8: 657-61.
14. Leide S, Diemer II, Ahlgren L, Mattsson S. In vivo distribution and dosimetry of Tc-99m MIBI in man. In: Proceedings of 5th international radiopharmaceutical dosimetry symposium. Watson EE, Schlafke-Stelson AT (eds). Oak Ridge Associated Universities. CONF 910529, 1992: 483-49.
15. Müller S, Guth-Tougelidis B, Creutzig H. Imaging of malignant tumors with Tc-99m-MIBI SPECT. J Nucl Med 1987; 28: 562.
16. Nemec J, Nyvltova O, Preiningerova M et al. Positive thyroid cancer scintigraphy using Tc-99m-tetrofosmin (Myoview): A preliminary report. Nucl Med Comm 1995; 16: 694-7.
17. Pacini F, Lippi F, Formica N, et al. Therapeutic doses of iodine-131 reveal un-diagnosed metastases in thyroid cancer patients with detectable serum thyro-globulin levels. J Nucl Med 1987; 28: 1888-91.
18. Ramanna L, Waxman A, Braunstein G. Thallium-201 scintigraphy in differentiated thyroid cancer: Comparison with radioiodine scintigraphy and serum thyroglobulin determinations. J Nucl Med 1991; 32: 441-6.
19. Sundram FX, Goh AS, Ang ES. Role of technetium-99mTc-99m-sestamibi in localization of thyroid cancer metastases. Ann Acad Med Singapore 1993; 22 (4): 557-9.
20. Van Sorge-Van Boxtel AJ, Van Eck-Smit BL, Goslings M. Comparison of serum thyroglobulin, I-131 and Tl-201 scintigraphy in the postoperative follow-up of differentiated thyroid cancer. Nucl Med Comm 1993; 14: 365-72.
21. Wackers FHT, Berman DS, Maddahi J, et al. Technetium-99m hexakis 2-methoxy-isobutyl isonitrile: Human biodistribution, dosimetry, safety, and preliminary comparison to Thallium-201 for myocardial perfusion imaging. J Nucl Med 1989; 30: 301-11.
22. Wawschinek O, Eber O, Petek W, et al. Determination of urine iodine excretion with a modified cer-arsenite method. Report of ÖGKG 1985; 8: 13-156.
23. Waxman AD, Ramanna L, Chapman N, et al. The significance of 1-131 scan doses in patients with thyroid cancer: determination of ablation: concise communication. J Nucl Med 1981; 22: 861.
24. Yen TC, Lin HD, Lee CH, et al. The role of Tc-99m-sestamibi whole-body scans in diagnosing metastatic Huerthle cell carcinoma of the thyroid gland after total thyroidectomy: a comparison with iodine-131 and Tl-201 whole body scans. Eur J Nucl 1994; 21: 980-3.